The Foundation supports research that can lead to the creation of better Parkinson's treatments. Here you can search previously awarded grants by keyword, program name, researcher name, institution or organization name and/or year.
FUNDED GRANTS ( 5)
Therapeutic Pipeline Program, 2015
There is a critical need for treatments that address depression and barriers to care among the approximately 5 million people living with Parkinson's disease (PD) worldwide. The purpose of this research is to test a new treatment (Telephone-Administered Cognitive Behavioral Therapy or T-CBT) for depression in PD. The treatment does not involve medication but teac...
Researchers: Roseanne D. Dobkin, PhD
LRRK2 Cohort Consortium, 2012
Parkinson's Institute LRRK2 Cohort: Clinical Phenotype, Pre/Non-Motor and Environmental Risk Assessment
The objective of this award is to better understand the clinical symptoms of patients that carry the most common genetic risk factor for PD the LRRK2 G2019S variant and what role this mutation plays in individuals that were exposed to environmental toxicants.
A novel feature of this work is the investigation of the effect of a second significant genetic cause of Parkinson's dise...
Researchers: Birgitt Schüle, MD, Dr. med.
Target Validation, 2006
Epidemiological and clinical studies have demonstrated that the prevalence of Parkinson's disease is 1.3 - 3.7 times greater in men than women. In support of this, several studies have also shown that hormone replacement therapy can further reduce the risk of PD in postmenopausal women. Studies in animal models of PD have shown a difference in susceptibility between genders, with males more vulner...
Cell Line, 2002
We have recently succeeded in differentiating adult human and animal bone marrow stromal stem cells (BMSCs) into neurons (nerve cells). A subpopulation of the neurons activates functions that are characteristic of the nerves that degenerate in Parkinson's disease. We are now isolating, expanding, and further differentiating the neurons for use in Parkinson's disease. Use of BMSCs for transplanta...
Researchers: Ira B. Black, MD
Fast Track, 2001
Glutathione depletion and mitochondrial defects have been implicated in the etiology of Parkinson's disease (PD). Our previous work examined the cellular mechanisms underlying dopamine cell loss in vitro and in vivo due to impairment of energy metabolism. We found that glutathione (GSH) plays a pivotal role in the susceptibility of dopamine neurons to disturbances in energy metabolism. This has le...
Researchers: Gail Zeevalk,